X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1882) 1882
index medicus (1542) 1542
animals (1430) 1430
mice (843) 843
antibodies (649) 649
single-chain antibodies - immunology (521) 521
cancer (508) 508
biochemistry & molecular biology (505) 505
single-chain antibodies - genetics (500) 500
biotechnology & applied microbiology (498) 498
proteins (492) 492
single-chain fv (478) 478
immunology (452) 452
single-chain antibody (437) 437
oncology (434) 434
expression (421) 421
viral antibodies (420) 420
cell line, tumor (407) 407
female (398) 398
medicine, research & experimental (369) 369
phage display (366) 366
immunotherapy (362) 362
amino acid sequence (326) 326
peptide library (313) 313
monoclonal-antibody (309) 309
molecular sequence data (308) 308
monoclonal antibodies (306) 306
monoclonal-antibodies (300) 300
antigens (295) 295
single-chain antibodies - chemistry (294) 294
escherichia-coli (280) 280
single-chain antibodies - metabolism (280) 280
research (271) 271
pharmacology & pharmacy (266) 266
enzyme-linked immunosorbent assay (255) 255
analysis (254) 254
in-vivo (254) 254
scfv (247) 247
health aspects (244) 244
article (237) 237
antibodies, monoclonal - therapeutic use (227) 227
therapy (225) 225
male (222) 222
immunoglobulins (220) 220
tumors (219) 219
biochemical research methods (218) 218
single-chain antibodies (217) 217
binding (215) 215
antibody (211) 211
antibodies, monoclonal - immunology (209) 209
recombinant fusion proteins - genetics (208) 208
biotechnology (205) 205
protein binding (203) 203
protein (200) 200
neoplasms - therapy (198) 198
neoplasms - immunology (191) 191
in-vitro (188) 188
cells (182) 182
recombinant proteins - genetics (181) 181
care and treatment (180) 180
gene expression (176) 176
single-chain antibodies - therapeutic use (175) 175
flow cytometry (173) 173
fragments (173) 173
cell line (172) 172
affinity (170) 170
single-chain antibodies - pharmacology (161) 161
research article (160) 160
antigen (157) 157
recombinant fusion proteins - immunology (157) 157
recombinant proteins - immunology (156) 156
cell biology (155) 155
medicine (154) 154
mice, inbred balb c (154) 154
mice, nude (154) 154
antibody specificity (153) 153
multidisciplinary sciences (149) 149
antibodies, monoclonal - genetics (148) 148
peptides (144) 144
protein engineering (144) 144
xenograft model antitumor assays (143) 143
immunoglobulin variable region - genetics (138) 138
t cells (138) 138
fusion protein (137) 137
cloning, molecular (134) 134
escherichia coli - genetics (132) 132
t-lymphocytes - immunology (132) 132
libraries (131) 131
antibody affinity (130) 130
physiological aspects (130) 130
escherichia coli (129) 129
biology (126) 126
gene therapy (126) 126
microbiology (126) 126
models, molecular (126) 126
genetic aspects (125) 125
immunoglobulin fragments - genetics (125) 125
apoptosis (124) 124
cytotoxicity (124) 124
antigens, neoplasm - immunology (123) 123
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Trends in Biotechnology, ISSN 0167-7799, 2013, Volume 31, Issue 11, pp. 621 - 632
Journal Article
Nature Communications, ISSN 2041-1723, 12/2018, Volume 9, Issue 1, pp. 877 - 12
HIV-1 broadly neutralizing antibodies (bNAbs) are being explored as passively administered therapeutic and preventative agents. However, the extensively... 
BISPECIFIC ANTIBODIES | SHIV INFECTION | POTENT NEUTRALIZATION | BROADLY NEUTRALIZING ANTIBODIES | MULTIDISCIPLINARY SCIENCES | IMPROVES PROTECTION | CD4 BINDING | HUMAN MONOCLONAL-ANTIBODIES | HUMAN-IMMUNODEFICIENCY-VIRUS | FITNESS COST | BREADTH | Protein Subunits - immunology | env Gene Products, Human Immunodeficiency Virus - immunology | Antiviral Agents - immunology | Humans | Epitopes - immunology | Antibodies, Neutralizing - immunology | env Gene Products, Human Immunodeficiency Virus - genetics | HIV Antibodies - immunology | Antiviral Agents - chemistry | Antibodies, Neutralizing - therapeutic use | env Gene Products, Human Immunodeficiency Virus - antagonists & inhibitors | Drug Design | Single-Chain Antibodies - therapeutic use | HIV Antibodies - therapeutic use | HIV Antibodies - pharmacology | Antiviral Agents - pharmacology | Single-Chain Antibodies - pharmacology | Antiviral Agents - therapeutic use | HIV-1 - drug effects | Antibodies, Neutralizing - pharmacology | Epitopes - genetics | HIV-1 - genetics | Microscopy, Electron | HIV Antibodies - chemistry | HIV-1 - immunology | Antibodies, Neutralizing - chemistry | HIV Infections - drug therapy | Mutation | Drug Combinations | Single-Chain Antibodies - chemistry | Single-Chain Antibodies - immunology | Antiviral agents | Antibodies | Crosslinking | Glycoproteins | Pharmacology | Epitopes | Chemical compounds | Glycan | CD4 antigen | Human immunodeficiency virus--HIV | Avidity | Binding sites | Neutralization
Journal Article
Neuron, ISSN 0896-6273, 01/2014, Volume 81, Issue 1, pp. 49 - 60
Although biotherapeutics have vast potential for treating brain disorders, their use has been limited due to low exposure across the blood-brain barrier (BBB).... 
CLATHRIN-MEDIATED ENDOCYTOSIS | TRANSFERRIN RECEPTOR | BARRIER | MICE | EXPRESSION | BINDING | NEUROSCIENCES | DELIVERY | Humans | Transcytosis - genetics | Protein Transport - physiology | Protein Transport - drug effects | Alzheimer Disease - pathology | Brain - metabolism | Dose-Response Relationship, Drug | Single-Chain Antibodies - metabolism | Lysosomes - metabolism | Time Factors | Protein Binding - drug effects | Amyloid beta-Peptides - metabolism | Single-Chain Antibodies - therapeutic use | Macrolides - pharmacology | Disease Models, Animal | Lysosomes - drug effects | Single-Chain Antibodies - pharmacology | Subcellular Fractions - drug effects | Alzheimer Disease - therapy | Enzyme Inhibitors - pharmacology | Presenilin-1 - genetics | Mice, Transgenic | Transcytosis - immunology | Protein Binding - immunology | Blood-Brain Barrier - drug effects | Receptors, Transferrin - metabolism | Subcellular Fractions - metabolism | Blood-Brain Barrier - metabolism | Brain - drug effects | Models, Immunological | Amyloid beta-Protein Precursor - genetics | Animals | Receptors, Transferrin - immunology | Amyloid beta-Peptides - immunology | Mice | Transcytosis - drug effects | Alzheimer Disease - genetics | Brain - immunology | Cell Line, Transformed | Viral antibodies | Analysis | Amyloid beta-protein | Antibodies | Chemical properties | Health aspects | Alzheimer's disease | Biopharmaceutics | Transferrin | Proteins | Cell culture | Ligands | Recycling | Membrane filters
Journal Article
Journal Article
Nature Reviews Cancer, ISSN 1474-175X, 11/2001, Volume 1, Issue 2, pp. 118 - 129
A quarter of a century after their advent, monoclonal antibodies have become the most rapidly expanding class of pharmaceuticals for treating a wide variety of... 
ENZYME PRODRUG THERAPY | B-CELL LYMPHOMA | COMPLEMENTARITY-DETERMINING REGIONS | ANTI-CD20 MONOCLONAL-ANTIBODY | ONCOLOGY | METASTATIC BREAST-CANCER | SINGLE-CHAIN FV | ACUTE MYELOID-LEUKEMIA | RESHAPING HUMAN-ANTIBODIES | ENDOTHELIAL GROWTH-FACTOR | HUMAN CARBOXYPEPTIDASE A1 | Prodrugs - administration & dosage | Recombinant Fusion Proteins - immunology | Antibodies, Neoplasm - therapeutic use | Immunotherapy - methods | Humans | Recombinant Fusion Proteins - therapeutic use | Neoplasm Proteins - immunology | Antibodies, Monoclonal - therapeutic use | Neoplasm Proteins - antagonists & inhibitors | Drug Delivery Systems | Neoplasm, Residual | Antibodies, Monoclonal, Humanized | Clinical Trials, Phase III as Topic | Neoplasms - therapy | Protein Engineering | Antibodies - immunology | Immunoconjugates - therapeutic use | Neoplasms - radiotherapy | Neovascularization, Pathologic - immunology | Antibodies, Monoclonal - immunology | Neovascularization, Pathologic - therapy | Antibodies - therapeutic use | Cytokines - therapeutic use | Antibodies, Neoplasm - immunology | Antibodies, Monoclonal, Murine-Derived | Antibody-Dependent Cell Cytotoxicity | Antigens, Neoplasm - immunology | Radioimmunotherapy | Rituximab | Treatment Outcome | Combined Modality Therapy | Cytokines - administration & dosage | Neoplasms - drug therapy | Xenograft Model Antitumor Assays | Antibodies, Bispecific - therapeutic use | Animals | Immunotoxins - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoplasms - immunology | Immunization, Passive | Mice | Liposomes | Neoplasms - pathology | Trastuzumab | Clinical Trials, Phase II as Topic | Viral antibodies | Usage | Care and treatment | Antibodies | Research | Health aspects | Methods | Cancer
Journal Article
Journal Article
Journal Article
Journal Article